155 related articles for article (PubMed ID: 24163092)
1. Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient.
Ferraro D; De Biasi S; Vitetta F; Simone AM; Federzoni L; Borghi V; Cossarizza A; Nichelli PF; Sola P
J Neuroimmune Pharmacol; 2013 Dec; 8(5):1059-61. PubMed ID: 24163092
[No Abstract] [Full Text] [Related]
2. Fingolimod modulates peripheral effector and regulatory T cells in MS patients.
Serpero LD; Filaci G; Parodi A; Battaglia F; Kalli F; Brogi D; Mancardi GL; Uccelli A; Fenoglio D
J Neuroimmune Pharmacol; 2013 Dec; 8(5):1106-13. PubMed ID: 23649711
[TBL] [Abstract][Full Text] [Related]
3. Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study.
Claes N; Dhaeze T; Fraussen J; Broux B; Van Wijmeersch B; Stinissen P; Hupperts R; Hellings N; Somers V
PLoS One; 2014; 9(10):e111115. PubMed ID: 25360562
[TBL] [Abstract][Full Text] [Related]
4. MS clinical trials: what can subgroup analyses teach us?
Rudick RA
Lancet Neurol; 2012 May; 11(5):386-8. PubMed ID: 22494954
[No Abstract] [Full Text] [Related]
5. Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
Voon V; Saiva L; O'Kelly S; Keane D
Eur J Clin Pharmacol; 2014 Mar; 70(3):373-5. PubMed ID: 24309839
[No Abstract] [Full Text] [Related]
6. FTY720 and central memory: out of sight, out of mind.
Slavin AJ; Zamvil SS
Neurology; 2010 Aug; 75(5):388-9. PubMed ID: 20610831
[No Abstract] [Full Text] [Related]
7. Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis.
Sato DK; Nakashima I; Bar-Or A; Misu T; Suzuki C; Nishiyama S; Kuroda H; Fujihara K; Aoki M
J Neuroimmunol; 2014 Mar; 268(1-2):95-8. PubMed ID: 24507619
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
Massberg S; von Andrian UH
N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
[No Abstract] [Full Text] [Related]
9. Multiple sclerosis: Cladribine--a contentious therapeutic contender for MS.
Hohlfeld R
Nat Rev Neurol; 2011 Jul; 7(8):425-7. PubMed ID: 21750524
[No Abstract] [Full Text] [Related]
10. [Dilemma of further therapeutic step in remitting-relapsing multiple sclerosis in case of ineffectiveness of first-line treatment: fingolimod or natalizumab?].
Gábor L
Ideggyogy Sz; 2014 Mar; 67(3-4):141. PubMed ID: 26118259
[No Abstract] [Full Text] [Related]
11. Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
Tur C; Montalban X
Mult Scler; 2014 Apr; 20(4):510-1. PubMed ID: 24468818
[No Abstract] [Full Text] [Related]
12. [The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis].
Kotov SV; Fedorova SI; Iakushina TI; Lizhdvoĭ VIu
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):74-8. PubMed ID: 23528598
[TBL] [Abstract][Full Text] [Related]
13. NICE rules out NHS prescription of fingolimod for multiple sclerosis.
Cohen D
BMJ; 2011 Aug; 343():d5117. PubMed ID: 21831936
[No Abstract] [Full Text] [Related]
14. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
Scott LJ
CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
[TBL] [Abstract][Full Text] [Related]
15. Oral cladribine and fingolimod for relapsing multiple sclerosis.
Mann H
N Engl J Med; 2010 May; 362(18):1738; author reply 1739-40. PubMed ID: 20445188
[No Abstract] [Full Text] [Related]
16. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.
Fazekas F; Berger T; Fabjan TH; Ledinek AH; Jakab G; Komoly S; Kraus J; Kurča E; Kyriakides T; Lisý L; Milanov I; Panayiotou P; Jazbec SS; Taláb R; Traykov L; Turčáni P; Vass K; Vella N; Havrdová E
Wien Med Wochenschr; 2012 Aug; 162(15-16):354-66. PubMed ID: 22895849
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod in a patient with Wolff-Parkinson-White syndrome.
Huys AC; Lalive PH; Sekoranja L
Mult Scler; 2014 Apr; 20(5):636-7. PubMed ID: 23897641
[No Abstract] [Full Text] [Related]
18. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
[TBL] [Abstract][Full Text] [Related]
19. Fingolimod for the treatment of relapsing multiple sclerosis.
Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
[TBL] [Abstract][Full Text] [Related]
20. Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.
Al-Hashel J; Ahmed SF; Behbehani R; Alroughani R
CNS Drugs; 2014 Sep; 28(9):817-24. PubMed ID: 25011422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]